Trevi Therapeutics

60 articles with Trevi Therapeutics

• Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

  11/11/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.

• Trevi Therapeutics to Present at Stifel Healthcare Conference - Nov 10, 2020

  11/10/2020

  Trevi Therapeutics, Inc. announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020.

• Trevi Therapeutics to Report Q3 2020 Financial Results on November 11Conference Call and Webcast to be Held at 4:30 p.m. ET

  11/4/2020

  Trevi Therapeutics, Inc. announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 11, 2020, to provide a corporate update and review the Company’s financial results for the third quarter ended September 30, 2020.

• Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™

  10/21/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today, announced updates to their ongoing clinical trials of Haduvio. Patient screening has resumed for the Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF),

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Trevi Therapeutics Announces the Hiring of Key TalentExpands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs

  10/13/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Shashank Rohatagi, Ph.D., as Vice President, Pharmacology and Clinical Pharmacokinetics, Farrell Simon, Pharm.D., as Vice President, Head of U.S. Marketing, and Katherine S. Takaki, Ph.D., as Vice

• Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

  9/9/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference

• Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update

  8/13/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2020, as well as recent business updates.

• Trevi Therapeutics to Report Q2 2020 Financial Results on August 13

  8/6/2020

  Trevi Therapeutics, Inc. announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 13, 2020, to provide a corporate update and review the Company’s financial results for the second quarter ended June 30, 2020.

• Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference

  8/5/2020

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ to treat serious neurologically mediated conditions, announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BTIG Biotechnology Conference on August 10, 2020:

• Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis

  7/13/2020

  Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO ™ as Proposed Trade Name for Nalbuphine ER  

• Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of DirectorsSeasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience

  6/30/2020

  Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors.

• Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference

  6/17/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), today announced that management will present via a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 23, 2020:

• Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders

  5/29/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders,

• Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update

  5/7/2020

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, announced financial results for the quarter ended March 31, 2020, as well as recent business highlights.

• TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE

  4/8/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 Needham Healthcare Conference

• TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE

  3/16/2020

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the quarter and year ended December 31, 2019, as well as recent business highlights.

• 

  BioSpace Movers & Shakers, Feb. 21

  2/21/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

• Trevi Therapeutics to Present at SVB Leerink Healthcare Conference

  2/20/2020

  Trevi Therapeutics, Inc. announced that management will present a Company overview, as well as host investor meetings, at the SVB Leerink 2020 Healthcare Conference

• Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of DirectorsSeasoned biopharmaceutical executive with over 30 years of drug development experience

  2/18/2020

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors.